Apparently the often-low standards for the FDA aren’t low enough. Now we just move trials to poor countries and use control arms that we wouldn’t approve here. VIVIO team member Bishal Gyawali writes about this in the Lancet. Look at the data yourselves and stop listening to the ‘experts’ who are paid to say ‘yes.’

VIVIO clinical team member, Bishal Gyawali, MD, PhD, is part of the team that develops the WHO Essential Medicines List (EML) identifies priority medicines that are most important to public health. Over time, the EML has included an increasing number of cancer medicines. See the details of their ground breaking work.

Mary Catherine Person and Jim Pursley have joined VIVIO as the company sees unprecedented demand for its specialty drug PBM carve-out services.

Mary Catherine is the former President of HealthSCOPE Benefits, a leading national Third-Party Administrator (TPA), which was sold to UnitedHealthcare in 2019. Ms. Person provided the following thoughts: “As a health plan sponsor, I had firsthand experience with a few specialty drugs accounting for more than 25% of our combined medical and pharmacy plan spend. As a Third-Party Administrator, we saw our customers constantly looking for answers to similar challenges. VIVIO offers plan sponsors the solution to solve the problem of high-cost specialty drugs and I couldn’t be more excited to help expand the mission.”

Jim was the Chief Commercial Officer for Livongo Health, which went public in 2019 before being acquired by Teledoc Health for $18.5B in 2020. Jim now serves as the President of Hinge Health, the leading Digital Musculoskeletal (MSK) Clinic for health plans and employers. Per Mr. Pursley: “Everywhere I go, I hear stories of employers and payors struggling with the rising cost of specialty drugs. Complex markets like this need innovative, transparent solutions that use data to drive personalized care. VIVIO’s next generation Specialty Drug management model efficiently removes waste from the system and improves outcomes for members. They are making significant progress and I am excited to support the VIVIO team.”

Pramod John, Founder and CEO of VIVIO, said “I know that Mary Catherine and Jim will provide unique perspectives as we continue to scale our operations to serve more and more customers. Our Specialty Drug Carve-Out solution works across pharmacy and medical benefits, and nobody understands benefit administration better than Mary Catherine. Jim has focused his career on employee benefit cost containment and improving health outcomes for members; that experience of listening to customers and improving the member experience will be crucial as we grow.”

About VIVIO: VIVIO Precision Care™ fixes the following system problems: identifying expensive drug therapies that don’t work even though they have FDA approval; not knowing if a member is responding adequately to the therapy; doctors not reading the clinical trials themselves; the arbitrary line between pharmacy and medical benefit; and, egregious supply chain waste. VIVIO uses clinical trial, patient, and financial data to drive better patient outcomes while eliminating wasted spend. The company’s carve-out program plugs into an employer’s current carriers and PBMs. 2020 net savings for VIVIO customers was 37%, while both outcomes and member experience significantly improved. In 2020, on average, VIVIO customers experienced a 7.5X ROI on program fees.

VIVIO Adds Industry Leaders to Advisory Board as Demand Increases for Transparent and Innovative Specialty Drug Management (prweb.com)

VIVIO clinical team member, Daniel Goldstein is referenced in Peter Bach’s scathing commentary in Health Affairs on the waste being driven by vial size games played by Pharma. The original article describes how Merck’s increase of vial size has led to billions of dollars of Keytruda being thrown away.

Visit W3Schools

VIVIO clinical team member, Bishal Gyawali, MD, PhD, on why financial toxicity deserves more attention. “The more lung cancer patients had to pay out of pocket for treatment, the less likely they were to adhere to, or continue, therapy, reported researchers, who also found an indication of resulting less-than-ideal survival odds.”

https://www.medpagetoday.com/reading-room/asco/lung-cancer/92003

Bishal Gyawali, MD, PhD, VIVIO clinical team member, interviewed. According to Gyawali, “what’s the point in having a drug that does not reach patients because of unaffordability? Both high cost and low probability of clinical benefit should make us question the value of a drug, not hail it as a game-changer.”

https://journals.lww.com/oncology-times/blog/3questionson/pages/post.aspx?PostID=149

San Leandro, CA – VIVIO, a leading specialty drug management company, announced today that Chris Crawford has joined the company as Chief Growth Officer. 

Chris is leveraging almost 20 years of employee benefits consulting and leadership experience to drive new client acquisition and build a sales organization.  Chris’ relevant experience includes Mercer, where he was the US Sales & Client Management Leader, before founding a benefits consulting firm, CMC Advisory Group, which was later acquired by Cottingham & Butler.  Most recently, Chris was the Chief Growth Officer at Health Strategy which is recognized as one of the premier pharmacy benefit consulting firms in the industry.

“The rising cost of specialty drugs is the most significant challenge facing employee benefit plans,” said Chris.  “Employers struggle with where to turn for help as the PBM industry is known for misaligned incentives, hidden vendor revenue streams and complex contracts.”

“We are excited to have Chris join our leadership team,” said Pramod John, VIVIO CEO.  “His deep industry experience will greatly benefit our current and future clients, stakeholders and the specialty drug industry as a whole.”

“I am proud to join the VIVIO team as I believe employers are looking for a specialty drug management solution that they can understand and trust.” said Crawford.  “VIVIO’S drug coverage decisions are driven by science and clinical data, rather than by supply chain profit motivation.  VIVIO also provides employers with a solution that is free from the conflicts of interest that exist when traditional PBMs are responsible for authorizing drug therapies that are then sold from their own specialty pharmacies.  Finally, employers and Plan Fiduciaries are looking for partners that charge a fair and transparent administration fee, while never receiving any other compensation or profiting from either drug cost inflation or an increase in utilization.”

*   *   *

About VIVIO: VIVIO Precision Care™ fixes the following system problems: identifying expensive drug therapies that don’t work even though they have FDA approval; not knowing if a member is responding adequately to the therapy; doctors not reading the clinical trials themselves; the arbitrary line between pharmacy and medical benefit; and, egregious supply chain waste. VIVIO uses clinical trial, patient, and financial data to drive better patient outcomes while eliminating wasted spend.  The company’s carve-out program plugs into an employer’s current carriers and PBMs.  2020 net savings for VIVIO customers was 37%, while both outcomes and member experience significantly improved.  In 2020, on average, VIVIO customers experienced a 7.5X ROI on program fees.

For more information or a higher res image, contact T. J. Tedesco at [email protected]

Minneapolis, MN, October 2019 – VIVIO, a specialty drug management company, won one of two innovator awards offered by Employer Health Innovation Roundtable.

About EHIR​

EHIR’s mission is to accelerate the adoption of innovation to improve health, wellness and productivity. EHIR provides objective support in identifying and assessing emerging solutions to sift through the noise and stay ahead of the curve amid a rapidly changing competitive landscape. EHIR has provided a streamlined process and valuable insights to leading employers for the last 5 years.

What is the EHIR Traction Award?

The Traction Award is a semi-annual award (Spring/Fall) recognizing the innovator, among these selected by our members to present, with the most employer interest through the EHIR matchmaking process. This award recognizes the importance of work in partnering with EHIR members to drive impact through action.

Why did EHIR create this award?

EHIR’s mission is to accelerate the adoption of innovation to improve the health, wellness, and productivity of employees and plan members. EHIR does this through a matchmaking process and it is through this commitment to action that innovation truly happens. The Traction Award was created to recognize the innovators who help EHIR deliver on its mission.

How are award winners determined?

The innovators with the greatest number of matches (between employer/innovator) during individual cohort meetings (Spring/Fall) is recognized as the winner. There are 4 winners each season as we have 4 employer cohorts.

Pramod John, PhD, CEO of VIVIO Health, discusses a recent presentation where he spoke about using real-world data to drive better outcomes and lower costs, as well as weighs the benefits of value-based care.

https://www.managedhealthcareconnect.com/articles/using-real-world-data-right-way